Repurposing Fostamatinib to Combat SARS-CoV-2-Induced Acute Lung Injury

doi:10.1016/j.xcrm.2020.100145

Cell Reports Medicine

Volume 1, Issue 8, 17 November 2020, 100145

https://doi.org/10.1016/j.xcrm.2020.100145 Get rights and content

Under a Creative Commons license

open access

A screen by Kost-Alimova et al.¹ suggests that the FDA-approved SYK inhibitor fostamatinib inhibits MUC1 in the respiratory tract and has the potential to treat serious outcomes of coronavirus COVID-19, including acute respiratory distress syndrome (ARDS) and acute lung injury (ALI).

Cell Reports Medicine

PreviewRepurposing Fostamatinib to Combat SARS-CoV-2-Induced Acute Lung Injury

Preview
Repurposing Fostamatinib to Combat SARS-CoV-2-Induced Acute Lung Injury